These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 30551175)

  • 61. CRISPR/Cas9 editing of the genome for cancer modeling.
    Guernet A; Grumolato L
    Methods; 2017 May; 121-122():130-137. PubMed ID: 28288827
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Live-Cell Imaging of Genomic Loci Using CRISPR/Molecular Beacon Hybrid Systems.
    Wu X; Ying Y; Mao S; Krueger CJ; Chen AK
    Methods Mol Biol; 2020; 2166():357-372. PubMed ID: 32710420
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Molecular basis for the PAM expansion and fidelity enhancement of an evolved Cas9 nuclease.
    Chen W; Zhang H; Zhang Y; Wang Y; Gan J; Ji Q
    PLoS Biol; 2019 Oct; 17(10):e3000496. PubMed ID: 31603896
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CRISPR/Cas9-mediated genome editing in plants.
    Liu X; Xie C; Si H; Yang J
    Methods; 2017 May; 121-122():94-102. PubMed ID: 28315486
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Heavily and fully modified RNAs guide efficient SpyCas9-mediated genome editing.
    Mir A; Alterman JF; Hassler MR; Debacker AJ; Hudgens E; Echeverria D; Brodsky MH; Khvorova A; Watts JK; Sontheimer EJ
    Nat Commun; 2018 Jul; 9(1):2641. PubMed ID: 29980686
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Type II anti-CRISPR proteins as a new tool for synthetic biology.
    Zhang Y; Marchisio MA
    RNA Biol; 2021 Aug; 18(8):1085-1098. PubMed ID: 32991234
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CRISPR-Cas9-Guided Genome Engineering in C. elegans.
    Kim HM; Colaiácovo MP
    Curr Protoc Mol Biol; 2016 Jul; 115():31.7.1-31.7.18. PubMed ID: 27366893
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficient and allele-specific genome editing of disease loci in human iPSCs.
    Smith C; Abalde-Atristain L; He C; Brodsky BR; Braunstein EM; Chaudhari P; Jang YY; Cheng L; Ye Z
    Mol Ther; 2015 Mar; 23(3):570-7. PubMed ID: 25418680
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evaluating and Enhancing Target Specificity of Gene-Editing Nucleases and Deaminases.
    Kim D; Luk K; Wolfe SA; Kim JS
    Annu Rev Biochem; 2019 Jun; 88():191-220. PubMed ID: 30883196
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Controlling and enhancing CRISPR systems.
    Shivram H; Cress BF; Knott GJ; Doudna JA
    Nat Chem Biol; 2021 Jan; 17(1):10-19. PubMed ID: 33328654
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Gene knockout in highly purified mouse hematopoietic stem cells by CRISPR/Cas9 technology.
    Dong Y; Bai H; Dong F; Zhang XB; Ema H
    J Immunol Methods; 2021 Aug; 495():113070. PubMed ID: 33957108
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Anti-CRISPR proteins targeting the CRISPR-Cas system enrich the toolkit for genetic engineering.
    Liu Q; Zhang H; Huang X
    FEBS J; 2020 Feb; 287(4):626-644. PubMed ID: 31730297
    [TBL] [Abstract][Full Text] [Related]  

  • 73. CRISPR/Cas9 can mediate high-efficiency off-target mutations in mice in vivo.
    Aryal NK; Wasylishen AR; Lozano G
    Cell Death Dis; 2018 Oct; 9(11):1099. PubMed ID: 30368519
    [No Abstract]   [Full Text] [Related]  

  • 74. CRISPR Mediated Genome Engineering and its Application in Industry.
    Kaboli S; Babazada H
    Curr Issues Mol Biol; 2018; 26():81-92. PubMed ID: 28879858
    [TBL] [Abstract][Full Text] [Related]  

  • 75. CRISPR as a Diagnostic Tool.
    Kim S; Ji S; Koh HR
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439828
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Highly Efficient and Rapid Detection of the Cleavage Activity of Cas9/gRNA via a Fluorescent Reporter.
    Yang Y; Liu S; Cheng Y; Nie L; Lv C; Wang G; Zhang Y; Hao L
    Appl Biochem Biotechnol; 2016 Oct; 180(4):655-667. PubMed ID: 27209600
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A CRISPR-Assisted Nonhomologous End-Joining Strategy for Efficient Genome Editing in Mycobacterium tuberculosis.
    Yan MY; Li SS; Ding XY; Guo XP; Jin Q; Sun YC
    mBio; 2020 Jan; 11(1):. PubMed ID: 31992616
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing.
    Kelkar A; Zhu Y; Groth T; Stolfa G; Stablewski AB; Singhi N; Nemeth M; Neelamegham S
    Mol Ther; 2020 Jan; 28(1):29-41. PubMed ID: 31601489
    [TBL] [Abstract][Full Text] [Related]  

  • 79. CRISPR/Cas9 Technology in Translational Biomedicine.
    Leonova EI; Gainetdinov RR
    Cell Physiol Biochem; 2020 Apr; 54(3):354-370. PubMed ID: 32298553
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Engineered RNA-Interacting CRISPR Guide RNAs for Genetic Sensing and Diagnostics.
    Galizi R; Duncan JN; Rostain W; Quinn CM; Storch M; Kushwaha M; Jaramillo A
    CRISPR J; 2020 Oct; 3(5):398-408. PubMed ID: 33095053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.